BRIEF-IDEAYA Biosciences Announces Selection Of Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-Small Cell Lung Cancer

Reuters04-22

April 22 (Reuters) - IDEAYA Biosciences Inc :

* IDEAYA BIOSCIENCES ANNOUNCES SELECTION OF MOVE-FORWARD PHASE 2 EXPANSION DOSE FOR IDE397 MONOTHERAPY IN MTAP-DELETION SQUAMOUS NON-SMALL CELL LUNG CANCER

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429945448?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-22 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429945448","market":"us","top_or_hot":-1,"title":"BRIEF-IDEAYA Biosciences Announces Selection Of Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-Small Cell Lung Cancer","media":"Reuters","content":"<html><body><p>April 22 (Reuters) - <a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> Inc   :</p><p>   * IDEAYA BIOSCIENCES ANNOUNCES SELECTION OF MOVE-FORWARD PHASE 2 EXPANSION DOSE FOR IDE397 MONOTHERAPY IN MTAP-DELETION SQUAMOUS NON-SMALL CELL LUNG CANCER</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-IDEAYA Biosciences Announces Selection Of Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-IDEAYA Biosciences Announces Selection Of Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 18:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 22 (Reuters) - IDEAYA Biosciences Inc   :   * IDEAYA BIOSCIENCES ANNOUNCES SELECTION OF MOVE-FORWARD PHASE 2 EXPANSION DOSE FOR IDE397 MONOTHERAPY IN MTAP-DELETION SQUAMOUS NON-SMALL CELL LUNG ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FORD","symbol_name":"福沃德工业","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2429945448","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429945448","pubTimestamp":1713780264,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 22 (Reuters) - IDEAYA Biosciences Inc   :   * IDEAYA BIOSCIENCES ANNOUNCES SELECTION OF MOVE-FORWARD PHASE 2 EXPANSION DOSE FOR IDE397 MONOTHERAPY IN MTAP-DELETION SQUAMOUS NON-SMALL CELL LUNG CANCERSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FORD":"福沃德工业","BK4139":"生物科技","IDYA":"IDEAYA Biosciences","BK4202":"服装、服饰与奢侈品"},"translate_title":"简介——IDEAYA Biosciences宣布为MTAP缺失鳞状非小细胞肺癌的IDE397单药治疗选择前移2期扩大剂量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FORD":1,"IDYA":1},"content_text":"April 22 (Reuters) - IDEAYA Biosciences Inc   :   * IDEAYA BIOSCIENCES ANNOUNCES SELECTION OF MOVE-FORWARD PHASE 2 EXPANSION DOSE FOR IDE397 MONOTHERAPY IN MTAP-DELETION SQUAMOUS NON-SMALL CELL LUNG CANCERSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429945448"}